Pharmaceuticals

Global Bi-Specific MAbS Market Overview: Trends Shaping Growth to 2029

November 7, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Is The Expected Total Market Size Of The Bi-Specific MAbS Industry By The Forecast Year 2029?

The bi-specific MAbS market has seen a rapid expansion in its size over recent years. It is anticipated to expand from $7.83 billion in 2024 to $9.05 billion in 2025, achieving a compound annual growth rate (CAGR) of 15.5%. Historically, this market’s growth can be attributed to factors such as elevated healthcare expenditure, increased funding, and various government initiatives.

The bi-specific MAbS market is anticipated to experience substantial growth over the next few years, with projections indicating it will expand to $14.89 billion by 2029, achieving a compound annual growth rate (CAGR) of 13.3%. This expansion during the forecast period is primarily driven by the increasing incidence of cancer, a growing aging population, and a rise in the prevalence of chronic diseases. Prominent trends for this period include a dedicated focus on technological advancements, continuous product innovation, the integration of artificial intelligence, increased investment in targeted and combination therapies, and the establishment of strategic partnerships.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3390&type=smp

What Are The Top Growth Drivers Impacting The Bi-Specific MAbS Market Outlook?

The rising prevalence of cancer and other chronic diseases is expected to fuel the growth of the bispecific monoclonal antibodies market throughout the forecast period. Bispecific monoclonal antibodies are created for the treatment of diverse cancers, infectious diseases, central nervous system disorders, and autoimmune disorders. These antibodies are regarded as more effective than traditional monoclonal antibodies (moAbs) since they target two or more tumor antigens on cells to impede cancer progression. For instance, in 2023, the Cancer Facts & Figures 2023 report, published by the American Cancer Society (ACS), a US-based voluntary health organization, estimated 609,820 cancer-related fatalities in the USA. Consequently, an increasing number of chronic diseases, including cancer, is anticipated to boost the demand for bi-specific MAbs to effectively treat these conditions.

Which Key Segments Fueling The Bi-Specific MAbS Market?

The bi-specific mabs market covered in this report is segmented –

1) By Type: Catumaxomab (Removab), Blinatumomab, Duligotumab, Emicizumab, Amivantamab, Faricimab, Teclistamab

2) By Product Type: In Vivo, In Vitro

3) By Indication: Cancer, Haemophilia A, Ophthalmic

4) By End Use: Hospitals, Research Institutes, Other End-Users

Subsegments:

1) By Catumaxomab (Removab): Cancer Therapy, Targeting EpCAM and CD3

2) By Blinatumomab: Acute Lymphoblastic Leukemia (ALL) Treatment, Targeting CD19 and CD3

3) By Duligotumab: Oncology Treatments, Targeting Epidermal Growth Factor Receptor (EGFR)

4) By Emicizumab: Hemophilia A Treatment, Targeting Factor IXa and Factor X

5) By Amivantamab: Non-Small Cell Lung Cancer (NSCLC) Therapy, Targeting EGFR And MET

6) By Faricimab: Ophthalmology Treatment (Wet Age-related Macular Degeneration, Diabetic Macular Edema), Targeting Angiopoietin-2 And VEGF-A

7) By Teclistamab: Multiple Myeloma Treatment, Targeting BCMA and CD3

What Trends Are Expected To Drive The Bi-Specific MAbS Market?

Firms within the bi-specific MAbs market are progressively channeling resources into diverse strategic endeavors, including cooperative agreements and alliances, aimed at broadening their product range and global footprint. Such a collaboration involves a cooperative venture among multiple organizations designed to achieve shared objectives. As an illustration, during October 2022, Gilead Sciences and MacroGenics, both US-based biopharmaceutical firms, initiated an exclusive partnership. This collaboration focuses on the development of MGD024, a bispecific antibody that targets CD123 and CD3 utilizing MacroGenics’ DART platform, alongside two additional bispecific research initiatives. This alliance provides Gilead with an exclusive licensing option for MGD024, a compound with the potential to address various hematologic cancers, such as acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). MGD024 is engineered to reduce cytokine-release syndrome (CRS) and permit intermittent administration, which could result in a more tolerable treatment experience and enhanced clinical results for patients suffering from AML and MDS.

Which Major Industry Participants Are Leading The Bi-Specific MAbS Market Growth?

Major companies operating in the bi-specific MAbS market include F. Hoffmann-La Roche AG, Amgen Inc, Johnson & Johnson, Sino Biological Inc, Kyowa Kirin, Zai Lab, Alphamab Oncology, Celldex Therapeutics, Biocon, EpimAb Biotherapeutics, ABL Bio, Takeda pharmaceuticals, Innovent Biologics, Merck & Co Inc, Eli Lilly Company Inc., AbbVie Inc, Bayer AG, Pfizer Inc, Novartis AG, GlaxoSmithKline, AstraZeneca, Cytiva, Bristol Myers Squibb, AbCellera, BioMarin Pharmaceuticals, Parexel, Sanofi S.A., Novo Nordisk A/S, BBI Solutions, Aspen Pharmacare, Amoun Pharmaceuticals CO Ltd, Baxter International, Cipla Medpro South Africa

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/bi-specific-mab-global-market-report

Which Global Regions Are Influencing The Competitive Landscape Of The Bi-Specific MAbS Market?

North America was the largest region in the bi-specific MAbs market in 2024. The regions covered in the bi-specific MAbs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request A Customized Version Of The Bi-Specific MAbS Market Report:

https://www.thebusinessresearchcompany.com/customise?id=3390&type=smp

Browse Through More Reports Similar to the Global Bi-Specific MAbS Market 2025, By The Business Research Company

Anti Hypertensive Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/anti-hypertensive-drugs-global-market-report

Pharmaceutical Api Manufacturing Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/pharmaceutical-api-manufacturing-global-market-report

Microbiome Therapeutics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/microbiome-therapeutics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795